A Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, PK and PD of LY4006895 in Healthy Volunteers and Patients With Early Symptomatic AD
Latest Information Update: 30 Oct 2024
At a glance
- Drugs LY-4006895 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 30 Oct 2024 New trial record